Allspring Global Investments’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$252K Buy
+26,613
New +$238K ﹤0.01% 1611
2025
Q4
– Sell
-27,957
Closed -$266K – 1744
2025
Q3
$266K Sell
27,957
-36
-0.1% -$280 ﹤0.01% 1505
2025
Q2
$185K Buy
+27,993
New +$185K ﹤0.01% 1551
2024
Q4
– Sell
-1,810
Closed -$22.9K – 2196
2024
Q3
$22.9K Hold
1,810
– – ﹤0.01% 1981
2024
Q2
$22.9K Buy
+1,810
New +$18.2K ﹤0.01% 2097
2023
Q4
– Sell
-12,075
Closed -$87.4K – 2570
2023
Q3
$87.4K Buy
12,075
+9,528
+374% +$76.1K ﹤0.01% 2052
2023
Q2
$18.9K Hold
2,547
– – ﹤0.01% 2467
2023
Q1
$17.6K Hold
2,547
– – ﹤0.01% 2525
2022
Q4
$26.2K Sell
2,547
-22,051
-90% -$389K ﹤0.01% 2532
2022
Q3
$447K Buy
24,598
+16,336
+198% +$708K ﹤0.01% 1607
2022
Q2
$424K Sell
8,262
-7,839
-49% -$406K ﹤0.01% 1619
2022
Q1
$1.19M Buy
16,101
+6,871
+74% +$613K ﹤0.01% 1783
2021
Q4
$1.32M Buy
+9,230
New +$1.59M ﹤0.01% 1767

Other funds holding NVAX

Allspring Global Investments's NVAX Position: Q2 2026 in Review

Allspring Global Investments opened a new position in Novavax (NVAX) in Q2 2026: 26,613 shares worth $252K. The stake represents ﹤0.01% of the portfolio and ranks #1611 among its holdings. This is a return to the name: Allspring Global Investments previously reported a position in NVAX as recently as Q3 2025.

Allspring Global Investments first reported a position in NVAX in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.32M in Q4 2021. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Allspring Global Investments held 26,613 shares of Novavax worth $252K as of Q2 2026.
  • Novavax was a new Allspring Global Investments position in Q2 2026.
  • Novavax made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1611 holding.
  • Allspring Global Investments first reported a position in Novavax in Q4 2021 and has held it in 13 quarters since.
  • Allspring Global Investments's Novavax position peaked at $1.32M in Q4 2021.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.